Interferons: signal, response and antiviral defense
Trace interferon production, receptor signaling and antiviral effectors; use controlled comparisons to separate a missing alarm from a failed response.
Is the problem making the signal, receiving it, or carrying out its instructions? Interferons let cells change their defenses before and during infection. By the end, you should be able to locate a failure from a few paired measurements, distinguish an antiviral program from one of its effectors, and explain why an interferon medicine is not interchangeable with every other interferon.
An alarm is not the same thing as a defense
An interferon is a secreted signaling protein. The cell releasing it and the cell responding to it can be different cells. Production measures the sender; response measures the receiver. A detectable concentration outside a cell therefore does not prove that the cell can respond. Human IFNAR2-deficiency experiments illustrate this separation: restoring a functional receptor restored the measured response to type I interferon. [1]
Type I interferons include interferon alpha and interferon beta. Think of an alarm that asks nearby workshops to prepare defenses, rather than a chemical that directly destroys every virus it touches. The responding cell uses its own gene-expression machinery to build an antiviral program. This can restrict several points in infection, but the relevant effectors depend on the virus and the cell. [2]
Autocrine means the signal acts back on the sending cell; paracrine means it acts on nearby cells. Neither word tells you whether a responding cell is already infected. An uninfected neighbor may prepare antiviral proteins before viral material reaches it. Keep that preparation distinct from the later activation of an individual enzyme.
Compare the two compartments: a missing signal and a cell that cannot receive it may need different experimental rescue tests. [1]If a sample contains interferon, what is still unknown about the receiving cell?
Whether its receptor and downstream signaling produce a functional response.
A useful first comparison is to give a known interferon preparation to the same cells. Rescue supports a defect upstream of the measured response. Failure to rescue leaves a receptor or downstream problem possible; it does not name one protein by itself. The paired controls in the practice cases make those distinctions narrower.
Locate the signal before naming the defect
Viral nucleic-acid sensing and interferon reception are different jobs. Cytoplasmic RNA sensors such as RIG-I and MDA5 can signal through MAVS, the mitochondrial antiviral signaling adaptor, to transcription factors including IRF3. This promotes interferon production. In a primary HCV study, the viral NS3/4A protease cut MAVS from its membrane location; a cleavage-resistant MAVS construct preserved interferon induction in the experimental system. That is a defect in sending an alarm, not evidence that the interferon receptor has disappeared. [4]
Many nucleated cells can contribute type I interferon, while plasmacytoid dendritic cells are particularly strong producers in relevant viral responses. IRF7 supports amplification of interferon production. A human IRF7-deficiency study found impaired responses in several cell preparations, including plasmacytoid dendritic cells and pulmonary epithelial cells. Do not turn this into a promise that every virus or tissue will have the same phenotype. [3]
On the receiving side, IFNAR contains the IFNAR1 and IFNAR2 subunits. The familiar signaling route uses JAK1 and TYK2, kinases that relay the signal by phosphorylation. Activated STAT1 and STAT2 associate with IRF9 to form ISGF3, a transcription-factor complex that drives interferon-stimulated genes. The abbreviation ISG simply means a gene whose expression responds to interferon. This is the principal canonical route, not a claim that these are the only signals any interferon can produce. [9]
Read measurements in their order: ligand outside the cell, receptor-linked STAT phosphorylation, induced transcripts and proteins, then effector activity. An intact early readout with a missing later one localizes the problem between them. A failure of every readout can also reflect a poor specimen or dead cells, so a viable-cell control matters.
Why does adding interferon help distinguish a production defect from a response defect?
It supplies a signal without requiring the tested cells to produce that signal.
One example is a patient-derived cell preparation with poor interferon release after RNA sensing, but normal STAT phosphorylation after supplied interferon. The receiving apparatus has passed that particular test. A second preparation with normal ligand release but absent responses to a known preparation needs a different investigation. Neither experiment alone establishes a patient's complete diagnosis.
The same receptor can also have partial defects. A human IFNAR1 study identified variants with impaired alpha or omega responses but preserved beta responses. This does not change the common receptor rule; it means that a complete receptor loss and a partial, ligand-selective variant need not produce the same pattern. [15]
A phosphorylation measurement reflects both addition and removal of phosphate groups. Protein-tyrosine phosphatases can limit interferon signaling; TYK2 is one experimentally demonstrated substrate. To distinguish a weak initial signal from a short-lived one, compare the initial response with its decay after new phosphorylation is stopped, and measure total protein alongside the phosphorylated fraction. That functional comparison does not by itself identify one regulatory protein. [24]
Preparing an effector does not mean it is active
Gene induction and enzyme activation are separate events. A cell can make more protein kinase R (PKR) after interferon exposure without immediately stopping all translation. In the canonical antiviral mechanism, an activating signal such as double-stranded RNA promotes PKR activation. Active PKR phosphorylates eukaryotic initiation factor 2 alpha, written eIF2alpha, reducing translation initiation. Other cellular stress kinases can also phosphorylate this target, so the measurement is not unique to PKR unless the experiment controls the alternatives. [2]
The second pathway acts on RNA itself. Activated 2',5'-oligoadenylate synthetase (OAS) produces short 2-5A molecules that activate RNase L. RNase L then cleaves RNA; its substrates are not limited to viral RNA. The shorthand is useful only when its roles stay separate: OAS makes the activating signal; RNase L performs the cleavage. [2]
Trace the output, not just the gene name. These are selected reactions, not the whole interferon response. [2]What can directly supplied 2-5A test when RNA cleavage is missing?
Whether the downstream RNase L reaction can respond when the OAS-produced activator is supplied.
Blocking one effector need not erase every antiviral action. In primary mouse and cell experiments, the contributions of PKR and RNase L varied between cell populations. This is why a decrease in protection is different from complete loss of protection. A measured translation effect also does not mean that every exposed cell must die. Cell survival, viral production, and RNA or protein synthesis are separate outcomes that need separate observations. [2]
Reovirus experiments provide a useful counterexample: PKR and RNase L contributed to host translation suppression without lowering infectious yield in the tested systems. A host response is not automatically a valid substitute for the viral outcome. Also check what an assay total is divided by. Fewer viable cells can lower total viral RNA without lowering RNA per surviving cell. [14]
Different receptors, overlapping immune effects
Type I is not a synonym for only antiviral, and type II is not a synonym for only inflammatory. Alpha and beta use IFNAR. Gamma is the type II interferon and uses a different receptor, IFNGR. Their biological effects overlap, even though receptor identity helps distinguish the signals. This is more reliable than sorting cytokines by a single word such as inflammation. [5]
In the canonical response, type I signaling prominently uses STAT1, STAT2, and IRF9 together; gamma prominently uses STAT1 homodimers. STAT1 is shared, so measuring phosphorylated STAT1 alone does not identify the ligand. The canonical kinase pairs also differ: JAK1/TYK2 serves the type I route, while JAK1/JAK2 serves the gamma route. Primary mutant-cell complementation established a JAK2-related gamma defect with retained alpha/beta responses. These are canonical comparisons, not a claim that kinase substitution is impossible in engineered systems. [21] Compare the receptor dependence and a second pathway readout. Likewise, a virus-related presentation does not establish that all other interferon responses are normal. [9]
A shared output is not proof of a shared receptor. The diagram compares two interferon families, not an exhaustive cytokine map. [5]If both samples phosphorylate STAT1, what additional comparison is useful?
Whether blocking IFNAR versus IFNGR removes the measured response.
Gamma can enhance macrophage functions and antigen presentation. [5] Type I responses can increase class I major histocompatibility complex (MHC) expression, helping display intracellular peptides to CD8 T cells. Gamma can increase class I as well as class II expression in receptive cells. Primary human-cell experiments show both the overlap and the importance of cell type; one keratinocyte experiment found class II induction with gamma but not alpha or beta in the tested range. This is not an exclusive, one-cytokine-only rule for every tissue. Increased display also does not create a matching antigen-specific T cell where none is present. A given T-cell clone may also require its peptide on a particular HLA allele. Selective HLA-A2 loss in melanoma illustrates why total class I staining alone does not establish the matching presentation target. [22][12][13]
Excess signaling can also injure tissue. A primary study of STING-associated vasculopathy identified gain-of-function variants with persistent interferon-pathway activity and inflammatory disease. This is a concrete counterexample to the claim that type I interferons cannot promote inflammation. It does not mean that every raised interferon signature proves a specific inherited disorder. [8]
Displaying a peptide also requires steps between the full-length intracellular protein and the surface peptide-HLA complex. A melanoma cell-line study found that restoring HLA-A2 alone did not restore recognition until antigen-processing functions were also increased. A short-peptide rescue can help test this interval; it does not identify one defective processing protein. Early T-cell activation and actual killing of the target remain separate measurements. [23]
Use the mechanism without overstating the medicine
A biological effect and a treatment indication are different claims. Interferon beta is used for relapsing forms of multiple sclerosis. Its prescribing information states that the precise mechanism of its clinical effect in MS is unknown. It is inappropriate to describe relapse reduction as proof that a hidden virus was eliminated or that one proposed immune pathway explains every patient's response. [6]
Interferon gamma-1b reduces the frequency and severity of serious infections associated with chronic granulomatous disease (CGD). That benefit does not require restoring the defective respiratory burst. The label states that phagocyte superoxide production does not increase even in treatment responders. A persistent abnormal oxidative-burst test is therefore not, by itself, proof that the treatment provides no clinical benefit. [5]
Older interferon-alpha associations should be read with their historical context. Current CDC guidance no longer recommends interferon-based regimens for hepatitis C; treatment uses direct-acting antivirals. Hairy cell leukemia also requires current disease-specific selection rather than automatically choosing the drug in an old cytokine mnemonic. The NCI summary discusses alternatives and limitations of available interferon preparations. [7][10]
After previous HCV infection, antibody may remain reactive without current viremia. RNA testing, not antibody persistence alone, identifies current infection. A negative RNA result usually means no current infection; recent exposure, new clinical concern or a poorly handled sample changes the follow-up question. [16]
Alpha preparations also have a history in hepatitis B, Kaposi sarcoma, melanoma and renal cell carcinoma. The PEGASYS label includes selected chronic hepatitis B use; it does not make alpha interchangeable across liver diseases. [11] Kaposi responses to interferon can be slow, so that historical association is not a prompt-control strategy for rapidly progressive symptomatic disease. [17] Melanoma and renal cancer decisions require their current stage-specific treatment frameworks, not an old cytokine list. [18][19]
Likewise, intralesional interferon for anogenital warts is an alternative with fewer efficacy data in CDC guidance, not a routine conclusion from the presence of HPV. Keep the host-directed antiviral mechanism, while checking the separate evidence for a particular treatment choice. [20]
Pegylation changes the protein drug's handling, not its interferon family. Polyethylene glycol is attached to the protein to prolong exposure. The PEGASYS label documents this chemistry and prolonged exposure. A product label and current treatment-selection guidance answer different questions; the HCV recommendation above still applies. A longer-lasting signal still needs a responsive receptor. [11]
Flu-like symptoms, injection-site reactions, blood-count changes, liver injury, and psychiatric symptoms need the medicine-specific safety context. For example, the interferon-beta label requires prompt reporting of depression or suicidal thoughts and monitoring for hepatic injury. Fever during treatment must not automatically be dismissed as a cytokine effect. A neutralizing-antibody result is also an assay result to interpret, not a stand-alone explanation for every clinical relapse. [6]
Does persistent abnormal superoxide testing rule out clinical benefit from interferon gamma in CGD?
No. Clinical benefit and correction of that laboratory defect are distinct outcomes.
Return to the main question whenever a case feels crowded: which part has actually been measured? Separate ligand production, receptor signaling, effector activation, and the outcome of interest. Then choose a comparison that can change the conclusion, instead of treating one familiar disease name as the answer.
A receiving problem can also be outside the cell. In an adult cohort with disseminated opportunistic infections, patient plasma could inhibit gamma signaling even when washed patient cells retained cytokine production and response. Functional testing distinguished neutralizing IgG from antibody binding alone. A low gamma readout in an intact-blood mitogen assay can therefore need a different explanation from failed T-cell production; sample quality and the clinical setting still matter. This does not make an indeterminate assay diagnostic of an autoantibody disorder. [25][26]
Apply the measurements
Use the stated clinical and laboratory conditions to distinguish interferon pathways. The explanations remain available on request before or after an attempt.
Case 1
Show answer and explanations for case 1
A. Neither recipient increases its type I response (Why this does not fit)
X responds to purified interferon beta. Y releases bioactive interferon that can stimulate the intact receiving pathway in X.
B. X increases its type I response; Y does not (Best answer)
The stimulated Y medium contains bioactive interferon. X responds to supplied interferon beta. Y has not responded to either supplied alpha or beta, even when ligand is available.
C. Both recipients increase their type I responses (Why this does not fit)
Y medium supplies the signal that X fails to produce. Purified type I ligands already failed to activate Y.
D. Y increases its type I response; X does not (Why this does not fit)
X produces little signal but retains the receiving response. Y releases an active signal but lacks the tested response to supplied type I ligand.
Takeaway: Follow the signal source and the receiving cell separately.
A. Alpha remains absent; gamma increases because IFNAR2 is shared (Why this does not fit)
Both alpha and beta use the type I interferon receptor. Gamma uses IFNGR rather than IFNAR2.
B. Alpha recovers only if ligand binding is further increased; gamma remains intact (Why this does not fit)
The supplied construct retains ligand binding. The full-length signaling tail is present in the construct that restores beta signaling.
C. Alpha responsiveness can recover; gamma responsiveness need not change (Best answer)
Ligand binding alone is insufficient for the measured receiving response. Alpha and beta share the IFNAR receptor apparatus. Gamma signaling was already intact through its distinct receptor.
D. Alpha and gamma both require the repaired IFNAR2 tail (Why this does not fit)
The alpha response shares IFNAR with beta. Gamma-induced gene expression was preserved before IFNAR2 reconstitution.
Takeaway: A shared type I receptor repair does not repair a separate intact pathway.
A. Interferon release is restored, but the IFNAR-dependent STAT response is blocked (Best answer)
The construct restores the tested MAVS-dependent interferon induction step. The antibody blocks extracellular ligand signaling through IFNAR. The type I receptor-dependent STAT response remains blocked despite restored release.
B. Both release and STAT activation are restored (Why this does not fit)
It protects MAVS-dependent interferon induction from the protease. The receptor is selectively blocked in the new well.
C. Release stays suppressed, while STAT activation is restored (Why this does not fit)
MAVS has been replaced with the cleavage-resistant construct. The IFNAR-blocking antibody interrupts reception of the newly released signal.
D. Both release and STAT activation stay suppressed because IFNAR lies upstream of MAVS (Why this does not fit)
The experiment explicitly holds the measured MAVS-dependent induction machinery intact. MAVS-dependent production precedes extracellular interferon reception through IFNAR.
Takeaway: Repairing the sender does not bypass a blocked receiver.
A. PKR-dependent initiation inhibition occurs; RNase L cleavage is lost (Why this does not fit)
PKR activation is intact. The substrate cannot be phosphorylated, while the separate RNA-cleavage arm remains functional.
B. Both initiation inhibition and RNA cleavage are lost (Why this does not fit)
PKR cannot phosphorylate the supplied eIF2alpha substrate. The separate OAS/2-5A/RNase L assay remains functional.
C. Both initiation inhibition and RNA cleavage occur because PKR abundance is normal (Why this does not fit)
The cells induce PKR protein and activate PKR after double-stranded RNA. The only eIF2alpha substrate cannot accept the PKR-dependent phosphorylation.
D. PKR-dependent initiation inhibition is lost; RNase L cleavage remains (Best answer)
PKR must phosphorylate eIF2alpha to produce the selected initiation-inhibition response. The replacement substrate cannot undergo that phosphorylation. The independent OAS/2-5A/RNase L reaction remains functional.
Takeaway: Test the substrate as well as the enzyme, and keep parallel outputs separate.
A. Measure OAS messenger RNA and repeat bulk RNA cleavage after interferon (Why this does not fit)
Interferon-stimulated transcripts increase normally. The experiment still would not distinguish OAS protein quantity from activity per molecule.
B. Measure RNase L protein and repeat cleavage with supplied 2-5A (Why this does not fit)
The extract can perform RNase L-dependent cleavage when the activator is supplied. Too little OAS protein and impaired OAS-specific activity remain distinct explanations.
C. Measure OAS protein and compare 2-5A production at matched OAS amounts with controlled RNA and ATP (Best answer)
The measured limitation precedes the rescued RNase L reaction. It tests whether too little OAS protein is present. Matched OAS amounts with controlled substrates compare activity per amount of enzyme.
D. Measure IFNAR abundance and compare STAT phosphorylation at increasing interferon doses (Why this does not fit)
The preparation increases interferon-stimulated transcripts. OAS protein quantity must be distinguished from OAS activity under controlled substrate conditions.
Takeaway: First localize the failure, then separate enzyme amount from enzyme activity.
A. Both RNase L wells cleave equally; PKR activity falls when 2-5A is removed (Why this does not fit)
Its 2-5A activator was removed and cannot be regenerated. The separate PKR/eIF2alpha assay is unchanged.
B. Cleavage returns in the 2-5A add-back well, not the vehicle well; the separate PKR response remains (Best answer)
Functional RNase L can restore cleavage when its activator is available. Only the add-back well has 2-5A available to activate the replacement enzyme. The separate PKR/eIF2alpha assay is unchanged.
C. Neither RNase L well cleaves because OAS protein itself must remain bound to RNase L (Why this does not fit)
OAS produces 2-5A. Fresh 2-5A can activate functional RNase L without requiring OAS to regenerate it.
D. The vehicle well cleaves preferentially because 2-5A suppresses RNase L (Why this does not fit)
It activates RNase L. The original successful RNase L rescue occurred in an extract that generated 2-5A.
Takeaway: RNase L protein and its activating signal are distinct requirements.
A. Assess long-term benefit with infection outcomes, and promptly evaluate the new focal illness for infection (Best answer)
The label reports benefit in CGD without increased phagocyte superoxide production. The patient has a sustained fever with new focal respiratory findings and an infiltrate. The new possible infection requires assessment independently of the earlier improvement in infection frequency.
B. Use persistent burst failure to classify treatment failure, and evaluate the lung findings for infection (Why this does not fit)
New focal respiratory findings warrant infection assessment. Superoxide production does not increase even in treatment responders.
C. Use the lower annual infection count as proof of protection, and manage this episode as a cytokine reaction (Why this does not fit)
It can be consistent with clinical benefit, without proving its exclusive cause. Sustained fever and a new focal infiltrate require a new assessment.
D. Defer interpretation of both outcomes until the oxidative burst improves (Why this does not fit)
No increase is required by the labeled CGD evidence. They raise a current concern for infection independently of the burst result.
Takeaway: Clinical benefit does not normalize the burst or exclude a new serious infection.
A. The IgG effect supports direct beta binding; a receptor-directed effect is excluded in this assay (Why this does not fit)
The inhibitory activity travels with patient IgG. It does not distinguish every ligand-specific effect from every possible receptor-directed effect.
B. The IgG effect supports IFNAR binding; a ligand-directed effect is excluded in this assay (Why this does not fit)
The tested beta preparation produces less response in the presence of patient IgG. Direct binding or a discriminating competition experiment is needed to localize the antibody target.
C. The IgG effect supports antibody-driven clinical failure; separate disease assessment adds little (Why this does not fit)
It measures beta bioactivity in donor cells. The clinical contribution to the patient disease course remains unestablished.
D. The IgG effect supports reduced beta bioactivity; its molecular target and clinical role remain unproven (Best answer)
The inhibitory activity is reversibly associated with the supplied patient IgG. Complete loss of every shared type I receptor response in donor cells is not supported. The molecular target of the IgG and its clinical contribution require separate evidence.
Takeaway: Separate reversible assay inhibition, molecular binding and clinical consequence.
A. The restored beta response remains; the gamma response falls (Best answer)
It restores the previously impaired beta response. The JAK1 and TYK2 pair remains available. The canonical gamma pathway requires JAK2, which is now inhibited.
B. Both responses fall after selective JAK2 inhibition (Why this does not fit)
JAK1 is shared. The inhibitor spares JAK1 as well as TYK2.
C. The restored beta response falls; the gamma response remains (Why this does not fit)
JAK1 and TYK2 serve that response. JAK2 participates in the gamma pathway.
D. Both responses remain after selective JAK2 inhibition (Why this does not fit)
It restored the type I response tested with beta. The canonical gamma response still needs its JAK2-associated receiving step.
Takeaway: A repaired type I response and a selective type II kinase block can have different outcomes.
A. Direct matched complexes into nuclei; compare promoter occupancy and steady-state reporter RNA (Why this does not fit)
It verifies arrival at the target DNA. A difference in RNA degradation can change steady-state abundance without changing new transcription.
B. Attach a nuclear-localization sequence; compare nuclear abundance and accumulated reporter protein (Why this does not fit)
It does not establish occupancy of the relevant promoter. RNA stability, translation and protein turnover can affect that endpoint.
C. Direct matched complexes into nuclei; compare promoter occupancy and newly synthesized reporter RNA (Best answer)
Failure of delivery remains possible despite normal cell-free DNA binding. It verifies that the complex reaches the reporter promoter. It measures the selected transcriptional output without substituting steady-state RNA or protein abundance.
D. Isolate nuclear complexes; compare binding to free reporter DNA and steady-state reporter RNA (Why this does not fit)
The purified complex can bind the reporter sequence. It leaves cellular promoter occupancy and the rate of new reporter transcription uncertain.
Takeaway: Verify target arrival before interpreting the direct transcriptional output.
A. Neither effector can act because receptor blockade instantly removes previously induced protein (Why this does not fit)
PKR and OAS protein remain at their measured induced abundance. Only one well receives the new double-stranded RNA activation stimulus.
B. The RNA-exposed well can activate the existing effectors despite absent new receptor signaling (Best answer)
It increased the abundance of PKR and OAS protein. It can activate these pre-existing effectors under the specified assay conditions. The short experiment preserves the already induced proteins needed for the tested reactions.
C. The RNA-free well activates more strongly because the RNA stimulus consumes the receptor signal (Why this does not fit)
The proteins were induced before ligand removal. The double-stranded RNA-exposed well has the activation stimulus.
D. Both wells show the same activation because equal protein abundance fixes enzyme activity (Why this does not fit)
The measured effector protein abundance is matched. The presence of activating double-stranded RNA differs.
Takeaway: Preparation and activation occur at different steps and times.
A. Measure infectious output at four, six and eight hours, with viable-cell counts at each time (Why this does not fit)
They first release measurable infectious virus at eight hours. Whether a delayed treated culture later reaches comparable total output remains unknown.
B. Measure infectious output at eight, sixteen and twenty-four hours, with viable-cell counts at each time (Why this does not fit)
It occurs at twenty-four hours. The treated culture may still be producing virus after the control has plateaued.
C. Follow infectious output until both cultures plateau, normalizing only to cells initially plated (Why this does not fit)
It permits detection of delayed catch-up. Different surviving-cell numbers can change infectious output despite equal starting counts.
D. Follow infectious output until both cultures plateau, recording viable-cell counts at each time (Best answer)
It must extend beyond the early release period and account for the plateau of each culture. They distinguish output differences from changes in the available viable target population. The assay measures infectious output rather than host translation or genome abundance.
Takeaway: Resolve the time course and its changing viable-cell denominator.
A. X: antigen-to-peptide display; Y: failure to trigger antigen-specific T-cell recognition (Why this does not fit)
Cognate short-peptide loading rescues activation after surface HLA-A2 and full-length antigen are available. Y already produces normal early antigen-specific activation despite low target-cell killing.
B. X: antigen-to-peptide display; Y: events between T-cell activation and target death (Best answer)
It identifies a remaining limitation between full-length antigen and cognate peptide display. Y displays the cognate complex and triggers normal early activation of the tested CD8 clone. Events after recognition, including effector engagement and target susceptibility, require separate investigation.
C. X: inadequate surface HLA-A2 abundance; Y: events between T-cell activation and target death (Why this does not fit)
X initially required HLA-A2 re-expression. After verified surface restoration, only cognate short-peptide loading rescues early recognition.
D. X: inadequate surface HLA-A2 abundance; Y: failure to trigger antigen-specific T-cell recognition (Why this does not fit)
Cognate peptide activates the clone on the HLA-A2-restored X cells. Early clone activation is normal even though target-cell killing is low.
Takeaway: Localize presentation failure separately from a failure after recognition.
A. A: type I ligand production; B: a class II expression step after early gamma signaling (Why this does not fit)
B retains early gamma signaling despite absent class II induction. A fails its early response to supplied beta.
B. A: complete shared STAT1 failure; B: complete gamma-receptor activation failure (Why this does not fit)
Gamma induces class II expression in A. B has a normal gamma-induced early STAT response.
C. A: type I reception through phosphorylation; B: class II regulation after the early gamma response (Best answer)
The A failure is at or before the measured beta-induced STAT phosphorylation. Class II induction fails despite its measured early gamma signal. Receptor, signaling and target-gene competence require further discriminating tests.
D. A: isolated late class I regulation; B: a proximal gamma-receptor kinase step (Why this does not fit)
Its early beta-induced STAT phosphorylation is absent. Its measured early gamma-induced STAT response is normal.
Takeaway: Localize the earliest missing response without claiming an identified receptor mutation.
A. Early recipient STAT is unchanged; later beta protein and bioactivity fall, and added beta restores the donor-cell assay (Best answer)
The early recipient STAT response is unchanged. Both later beta protein and bioactivity fall after input ligand has been removed and recipient production is suppressed. It demonstrates that the later donor-cell assay can still respond to supplied beta.
B. Early recipient STAT and later activity both fall, without testing beta add-back in the donor assay (Why this does not fit)
Reduced initial reception could account for less later production. Without add-back, the competence of the donor-cell bioassay remains untested.
C. Early recipient STAT is unchanged; later beta protein is unchanged while bioactivity falls and add-back also fails (Why this does not fit)
Later beta protein remains unchanged. A downstream inhibitory or bioassay problem remains possible.
D. Early recipient STAT is unchanged; IFNB1 RNA falls but later beta protein and bioactivity remain unchanged (Why this does not fit)
Only the measured IFNB1 RNA is reduced. The later beta protein and donor-cell bioactivity remain unchanged.
Takeaway: Separate preserved priming, reduced new ligand and a functioning downstream bioassay.
A. Both constructs show absent early beta signaling, while gamma-induced genes remain intact (Why this does not fit)
It argues against complete loss of every shared STAT-dependent response. Neither construct restores the early beta response.
B. Both constructs restore beta signaling equally, and gamma-induced genes remain intact (Why this does not fit)
The functional construct must differ from its matched empty-vector control. It leaves a nonspecific preparation or vector-associated change as an explanation.
C. Only IFNAR2 restores early beta phosphorylation, but late beta and gamma gene responses remain absent (Why this does not fit)
The early receiving-to-phosphorylation response improves. Absent late beta and gamma responses leave downstream transcriptional dysfunction possible.
D. Only IFNAR2 restores early and late beta responses, while gamma-induced genes were already intact (Best answer)
Restoration of the measured beta response is specific to functional IFNAR2 in this experiment. The downstream machinery can produce the tested beta-induced gene response. It argues against complete loss of the shared STAT response in these cells.
Takeaway: Specific complementation plus a separate intact response supports a correctable receiving limitation.
A. The conjugated formulation has higher per-concentration receptor activity and bypasses receptor loss (Why this does not fit)
The two formulations induced similar responses in receptor-intact cells. Neither formulation restored their response.
B. Conjugation can extend exposure without establishing greater intrinsic activity or receptor independence (Best answer)
The conjugated formulation declines more slowly in blood. Equal concentrations produce similar measured responses in intact cells. Cells lacking the receptor fail to respond to either formulation.
C. The slower decline establishes a different interferon family with a different receiving receptor (Why this does not fit)
Polyethylene glycol is attached to the parent protein. Both preparations fail in cells completely lacking the relevant receiving receptor.
D. The equal-concentration cell responses establish identical duration of exposure in the patient (Why this does not fit)
The measured concentrations of the two preparations are equal. The conjugated formulation declines more slowly.
Takeaway: Separate drug persistence, concentration-response and receptor requirement.
A. The cell assay supports preserved reception; repeat the old interferon course before considering a different regimen (Why this does not fit)
The tested receiving pathway remains functional. Current disease-specific guidance, not pathway competence alone, governs treatment selection.
B. The cell assay supports restored antiviral control; confirm that control with antibody alone before further treatment assessment (Why this does not fit)
HCV RNA is detectable. Antibody reactivity does not establish whether current viremia has cleared.
C. The cell assay argues against complete reception failure; assess a current direct-acting antiviral regimen for the RNA-positive infection (Best answer)
The cells do not show complete loss of the tested interferon receiving response. Detectable HCV RNA establishes current infection. Current CDC guidance favors direct-acting antivirals rather than escalation of an old interferon regimen.
D. The cell assay establishes the cause of prior nonclearance; choose a new regimen solely from its STAT response (Why this does not fit)
The experiment did not reproduce or explain the prior clinical nonclearance. It does not compare the clinical suitability of current antiviral regimens.
Takeaway: Functional reception and current viremia are separate inputs to treatment interpretation.
A. The results do not show current HCV infection; persistent antibody alone is not a reason to restart interferon (Best answer)
It can reflect prior exposure and does not establish ongoing infection. It indicates no current infection detected in the absence of a new exposure concern. It does not justify retreatment, and current HCV treatment guidance does not favor interferon-based regimens.
B. Reactive antibody overrides negative RNA and establishes a need for interferon retreatment (Why this does not fit)
The current RNA test is negative. Antibody can remain reactive after past infection.
C. Negative RNA proves the antibody result is false and that no past infection occurred (Why this does not fit)
HCV antibody can remain detectable. No current infection is detected in the stated setting.
D. Repeat antibody titers until they become negative before interpreting treatment response (Why this does not fit)
HCV RNA testing identifies current infection. Antibody can persist without detectable current viral RNA.
Takeaway: Antibody reactivity and current viral RNA answer different questions.
A. A plasma IgG-associated inhibition is supported; its activity is established as selective neutralization of gamma (Why this does not fit)
An inhibitory effect is associated with the patient IgG fraction. The same total IgG preparation also lowers the alpha-induced STAT1 response. The gamma-binding subset has not been functionally separated from the rest of the inhibitory IgG preparation.
B. A fixed intrinsic gamma-receiving defect is supported; its activity is established as selective neutralization of gamma (Why this does not fit)
Washed patient leukocytes respond to both ligands in control serum. The transferred total IgG inhibits both gamma- and alpha-induced responses. It cannot assign the observed inhibition to a gamma-specific antibody mechanism.
C. A fixed intrinsic gamma-receiving defect is supported; the inhibitory activity is not established as gamma-selective (Why this does not fit)
Gamma selectivity has not been established because both ligand responses are inhibited. The response depends on the plasma environment and is transferred and reversed with the IgG fraction.
D. A plasma IgG-associated inhibition is supported; the inhibitory activity is not established as gamma-selective (Best answer)
They support an extracellular IgG-associated inhibitory effect rather than a fixed intrinsic defect in the tested patient cells. They link the reversible inhibition to the tested total IgG fraction. Both gamma and alpha responses are inhibited, and the gamma-binding subset has not been isolated and tested.
Takeaway: Localize the inhibitory compartment and test specificity as separate conclusions.
A. The preserved beta response excludes any contribution from the IFNAR receptor (Why this does not fit)
Introducing the variant reproduces the differential alpha and beta responses. A partial IFNAR1 effect need not abolish all responses through that receptor.
B. A ligand-selective receptor impairment is supported, rather than complete absence of all type I receptor function (Best answer)
It supports a contribution of the receptor variant to the measured ligand-selective defect. Complete IFNAR1 loss abolishes both tested responses. The variant is not behaving as complete loss of all tested type I receptor function.
C. The variant demonstrates that alpha and beta normally use unrelated receptors (Why this does not fit)
IFNAR1 is manipulated. Both alpha and beta responses require the intact type I receptor apparatus in that control.
D. The variant proves that every infection in the patient results from total interferon unresponsiveness (Why this does not fit)
The beta response is retained. The experiment does not establish the cause of every clinical infection.
Takeaway: Compare a partial variant with a true null control.
A. Viral RNA per viable cell falls by half, proving reduced infectious output (Why this does not fit)
Two million copies divided by one million viable cells gives two copies per viable cell. Four million copies divided by two million viable cells also gives two copies per viable cell.
B. The equal per-cell values prove that interferon had no biological effect (Why this does not fit)
The exposed culture contains half as many viable cells at sampling. It cannot establish that every biological effect is absent.
C. Total RNA is lower, but RNA per viable cell is unchanged and infectious output remains unmeasured (Best answer)
Both are halved in the exposed culture. Both cultures contain two measured RNA copies per viable cell. Infectious viral output has not been measured.
D. The lower viable-cell count proves RNase L selectively destroyed viral rather than host RNA (Why this does not fit)
It does not identify the cause of the viable-cell difference. RNase L substrates are not restricted to viral RNA.
Takeaway: Separate total signal, surviving-cell normalization and infectious output.
A. Binding antibody is detected, but neutralization and causation of the new lesion are not established (Best answer)
It detects antibody binding to the tested drug preparation. The patient IgG does not show reduced beta bioactivity under the tested conditions. These results do not establish that antibodies caused the new lesion.
B. The binding result establishes neutralization even though the functional response is retained (Why this does not fit)
The known neutralizing-antibody control reduces the response. It does not reduce the measured beta-induced gene response.
C. The normal functional assay proves the patient cannot develop neutralizing antibodies later (Why this does not fit)
The current patient IgG and specified drug-bioactivity conditions are tested. It does not establish all future antibody or clinical responses.
D. The new MRI lesion invalidates the normal cell assay and proves its result is false (Why this does not fit)
Its positive neutralizing control reduced the gene response. The lesion alone does not establish antibody-mediated loss of drug bioactivity.
Takeaway: Binding, functional inhibition and clinical causation require different evidence.
A. Both failures are localized to ligand availability because the same late reporter is low (Why this does not fit)
Both preparations bind the supplied ligand. A lacks early kinase and STAT responses, while B retains phosphorylation but lacks the specified complex.
B. A requires only a late complex repair; B requires only more receptor stimulation (Why this does not fit)
It occurs at or before the receptor-associated kinase response. B already has early STAT phosphorylation but fails at the specified complex.
C. An active reporter construct would prove the same endogenous gene is defective in both (Why this does not fit)
It can test whether the late reporter machinery can respond to a direct transcriptional input. It would not identify the endogenous defective gene in either preparation.
D. Test a proximal receiving rescue in A and complex-level rescue in B, using the active construct as a downstream-capacity control (Best answer)
The early kinase or receiving-signaling level fails. The failure lies after phosphorylation at formation of the specified complex. It controls whether the downstream reporter machinery remains capable of responding.
Takeaway: An early-versus-late comparison narrows functional location without naming a gene.
A. Combined treatment retains 20% yield despite reduced measured induction; fresh interferon also gives 20% yield (Why this does not fit)
Reduced measured induction has not caused loss of the protective effect. Unmeasured effectors or induction-independent contributions remain possible.
B. Combined treatment gives near-control yield with reduced induction; fresh interferon restores induction and 20% yield (Best answer)
Reduced induction accompanies loss of the protective yield reduction. Fresh inhibitor-free pretreatment restores induction and the protective response. The pattern supports an induced host program but does not exclude every transient off-target effect or identify one effector.
C. Combined treatment gives near-control yield with normal induction; fresh interferon retains normal induction and 20% yield (Why this does not fit)
The measured interferon-induced program remains normal. Another transient effect remains possible when induction itself is preserved.
D. Combined treatment retains 20% yield with normal induction; fresh interferon retains both measurements (Why this does not fit)
Measured induction remains normal. The protective yield reduction remains unchanged. The comparison has not removed the program to test whether protection depends on it.
Takeaway: A reversible induction-output association supports a host program without proving one molecular cause.
